Related Experiment Video
Updated: Mar 31, 2026

Enhancing Tumor Content through Tumor Macrodissection
Published on: February 12, 2022
Subtype-specific therapy for DLBCL: are we there yet?
Nadia Khan1, Richard I Fisher1
1FOX CHASE CANCER CENTER.
Abstract:
In this issue of Blood, Offner et al report the results of LYM-2034, a phase 2 multinational trial in which 164 patients with nongerminal center B-cell–like diffuse large B-cell lymphoma (non-GCB DLBCL) were randomized to receive rituximab, cyclophosphamide, adriamycin, prednisone, and either vincristine (R-CHOP) or bortezomib (VR-CAP). DLBCL, previously recognized as a single disease entity, represents a heterogeneous group of diseases.
More Related Videos
12:55Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Special Features of Adaptive Immunity
The primary cell types involved in adaptive immunity are T cells and B cells. Each type has a unique role in defending the body against pathogens. T cells are responsible for cell-mediated immunity. They identify and eliminate infected cells directly,...